Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

AHCO vs AXGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

AXGN Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 4–5 Matrix Metrics)

AXGN Overall Winner 6-Pillar Tally: AHCO 1 – 5 AXGN Matrix Metrics: AHCO 5 – 4 AXGN

As of Nov 20, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas AXGN carries 35.7/100 (SELL) at $55.75 (79.0x Forward P/E, -5.2% operating margin).

  • Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. AXGN 35.7/100 SELL), AXGN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 3.8% operating margin) and revenue trajectory (+26.2% vs. +10.9% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About AHCO vs AXGN
AHCO NASDAQ
AdaptHealth Corp. Common Stock
Services-Home Health Care Services
$7.20
-0.69% 1D
Market Cap $989.8M
TTM Revenue $3.44B
Forward P/E 7.8x
Beta / 30D Vol 0.17β · 67% Vol
Unified Composite Score
45.2 / 100 HOLD
Tech 29.0 Fund 46.0 Flow 54.0 Mom 60.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (7.8% over 20 days), RSI 57
RSI-14: 57.1 · SMA20: $6.96 · SMA50: $6.32
AXGN NASDAQ Head-to-Head Winner
Axogen, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$55.75
-1.06% 1D
Market Cap $3.4B
TTM Revenue $267M
Forward P/E 79.0x
Beta / 30D Vol 1.22β · 121% Vol
Unified Composite Score
35.7 / 100 SELL
Tech 50.0 Fund 30.0 Flow 64.0 Mom 31.6
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (2.5% over 20 days), RSI 66
RSI-14: 66.4 · SMA20: $51.22 · SMA50: $44.34

6-Pillar Scorecard Institutional Category Breakdown (AHCO 1 – 5 AXGN)

Columns: Metric · AHCO · AXGN
1. Valuation Multiples AHCO
Forward P/E 7.8x 79.0x
Trailing P/E 7.8x 125.0x
PEG Ratio N/M N/M
EV / Revenue 0.9x 11.5x
2. Growth & Scale AXGN
Revenue Growth (YoY) +10.9% +26.2%
Earnings Growth (YoY) +6.7% +300.0%
TTM Revenue (USD) $3.44B $267M
Market Cap $989.8M $3.4B
3. Profitability & Quality AXGN
Gross Margin 18.2% 74.2%
Operating Margin 3.8% -5.2%
Net Profit Margin -11.8% -12.0%
Return on Equity (ROE) -28.4% -10.3%
4. Balance Sheet & Cash Flow AXGN
Cash Generation (TTM) $82M $20M
Cash Flow Margin 2.4% 7.5%
Net Cash / Leverage $1.97B Net Debt (1.67x D/E) $309M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning AXGN
Options Structure Phase SURGE SURGE
Current IV / %ile 66.9% (12th %ile) 72.6% (17th %ile)
Put/Call OI Skew N/A 0.10x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup NEUTRAL · Markup
6. R&D & Supply-Chain Moat AXGN
OpEx & R&D Intensity 14.4% of Rev ($495M) 79.4% of Rev ($212M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: AHCO (5) vs AXGN (4)
Institutional Metric AHCO AXGN Criterion Row Edge
Market Capitalization
Scale
$989.8M $3.4B Larger Scale AXGN
Trailing P/E Ratio
Valuation
7.8x 125.0x Lower Multiple AHCO
Forward P/E Ratio
Valuation
7.8x 79.0x Lower Multiple AHCO
Revenue Growth (YoY)
Growth
+10.9% +26.2% Higher Growth AXGN
Operating Margin (TTM)
Profitability
3.8% -5.2% Higher Margin AHCO
Net Profit Margin
Profitability
-11.8% -12.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-28.4% -10.3% Higher ROE AXGN
52-Week Range Position
Momentum
24% ($5–$13) 89% ($24–$60) Stronger Trend AXGN
Beta / 30D Volatility
Risk Regime
0.17β · 67% Vol 1.22β · 121% Vol Lower Realized Risk AHCO
Unified Institutional Score
Composite Signal
45.2 / 100 (HOLD) 35.7 / 100 (SELL) Higher Composite AHCO
Trailing 12M Revenue (USD)
Operating Scale
$3.44B $267M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
18.2% 74.2% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.9x EV/Rev N/M PEG · 11.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$82M ($1.97B Net Debt (1.67x D/E)) $20M ($309M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon AXGN +35.3 pp
AHCO: +16.69% · AXGN: +51.99%
3M Horizon AHCO +14.65 pp
AHCO: +27.89% · AXGN: +13.24%
6M Horizon AXGN +67.41 pp
AHCO: -31.1% · AXGN: +36.31%
1Y Horizon AXGN +141.58 pp
AHCO: -20.88% · AXGN: +120.7%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period AHCO Revenue AXGN Revenue AHCO Op. Margin AXGN Op. Margin Margin Leader
FY2018 $350M $80M 9.0% -24.4% AHCO
FY2019 $530M $110M 5.5% -29.4% AHCO
FY2020 $1.06B $110M 6.8% -20.6% AHCO
FY2021 $2.45B $130M 9.2% -20.0% AHCO
FY2022 $2.97B $140M 6.4% -21.4% AHCO
FY2023 $3.20B $160M -18.7% -13.5% AXGN
FY2024 $3.26B $190M 8.1% -1.8% AHCO
FY2025 $3.24B $230M 2.8% -3.5% AHCO

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
AHCO SURGE
6d in phase · OBV NEUTRAL
Current IV 66.9%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AHCO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
AXGN SURGE
7d in phase · OBV NEUTRAL
Current IV 72.6%
IV Percentile 17th %ile
Put/Call OI Skew 0.10x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact AXGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
AHCO Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $989.8M market capitalization and 3.8% operating margin.
OpEx & R&D Reinvestment 14.4% of Rev ($495M)
90D Engineering Disclosures 0 Published
AXGN Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $3.4B market capitalization and -5.2% operating margin.
OpEx & R&D Reinvestment 79.4% of Rev ($212M)
90D Engineering Disclosures 0 Published

Investor FAQ AHCO vs AXGN Key Questions & Quantitative Answers

As of Nov 20, 2026, Axogen, Inc. (AXGN) is the stronger overall head-to-head candidate over AdaptHealth Corp. (AHCO) in the Tradestie Institutional Equity Comparison Engine, winning 4–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). AHCO carries a Unified Composite Score of 45.2/100 (HOLD) at $7.20 (7.8x Forward P/E, 3.8% operating margin), whereas AXGN carries 35.7/100 (SELL) at $55.75 (79.0x Forward P/E, -5.2% operating margin). Composite vs. Pillar Nuance: While AHCO currently prints a higher short-term Unified Composite Score (45.2/100 HOLD vs. AXGN 35.7/100 SELL), AXGN captures the overall institutional head-to-head verdict (4–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (-5.2% vs. 3.8% operating margin) and revenue trajectory (+26.2% vs. +10.9% YoY).

AXGN leads the Growth & Scale pillar: AHCO posts +10.9% YoY revenue growth and +6.7% YoY earnings growth on $3.44B TTM revenue (18.2% gross margin, 3.8% operating margin), compared with AXGN at +26.2% YoY revenue growth and +300.0% YoY earnings growth on $267M TTM revenue (74.2% gross margin, -5.2% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), AHCO cumulative revenue shifted +825.7% while AXGN shifted +187.5%. In operating R&D and SG&A reinvestment, AHCO deploys 14.4% of Rev ($495M) (0 90-day corporate R&D disclosures) versus 79.4% of Rev ($212M) (0 disclosures) for AXGN.

AHCO screens cheaper on headline valuation multiples. AHCO trades at 7.8x Forward P/E, 7.8x Trailing P/E, N/M PEG, and 0.9x EV/Revenue (2.4% FCF margin), whereas AXGN trades at 79.0x Forward P/E, 125.0x Trailing P/E, N/M PEG, and 11.5x EV/Revenue (7.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against AHCO (-28.4% ROE) versus AXGN (-10.3% ROE) capital efficiency.

In options market volatility and institutional positioning, AHCO carries 66.9% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (0.17β · 67% Vol realized risk). By comparison, AXGN carries 72.6% implied volatility (17th %ile, Compressed (<25th %ile)), a 0.10x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.22β · 121% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.